1. A and B, intratumoral DC-AdCCL21 leads to reduction in growth rates of bilateral tumors.
A and B, intratumoral DC-AdCCL21 leads to reduction in growth rates of bilateral tumors. L1C2 tumor cells (1.5 × 105) were inoculated on the right suprascapular area and 2 × 104 L1C2 tumor cells on the left in BALB/c mice. Five days after tumors were established, mice were treated intratumorally on the right side only with diluent, DC-AdCCL21, AdCCL21 (106 plaque-forming units), and fibroblast-AdCCL21. Compared with diluent controls, there was a systemic reduction of the bilateral tumors in the following treatment groups, AdCCL21 and fibroblast-AdCCL21. However, compared with diluent-treated control or fibroblast-AdCCL21 treatment groups, the DC-AdCCL21 group evidenced the most significant systemic reduction in bilateral tumors (P < 0.01, compared with diluent treated control and *, P < 0.05 compared with fibroblast-AdCCl21 treatment group; n = 8 mice/group). Forty three percent of mice treated with DCAdCCL21 showed complete regression of both flank tumors, whereas only 14 percent of mice treated with fibroblast-AdCCL21 showed complete tumor eradication in the treatment flank only. Results are representative of three independent experiments; bars, ±SD.
Seok-Chul Yang et al. Clin Cancer Res 2004;10:
©2004 by American Association for Cancer Research